Core Insights - LIXTE Biotechnology's LB-100 is highlighted as a revolutionary cancer therapy that induces "lethal activation" in cancer cells, particularly colon cancer, leading to cell death [1][3] - The editorial in Nature Reviews Cancer emphasizes LB-100's unique mechanism of hyperactivating oncogenic signaling, which contrasts with traditional therapies that inhibit these pathways [4][7] - LIXTE is advancing its clinical trials for LB-100, which has shown a favorable toxicity profile and preliminary antitumor activity in phase I trials [6][10] Mechanism of Action - LB-100, a first-in-class PP2A inhibitor, hyperactivates oncogenic pathways, creating mitogenic stress that is lethal to tumor cells, especially when combined with stress-response inhibitors [5][11] - The approach targets the ideal level of oncogenic signaling, pushing it beyond survivable thresholds, which may represent a vulnerability in tumors [4][12] - Recent data indicate that LB-100's combination with WEE1 inhibitors can trigger tumor regression in colorectal and pancreatic cancer models [11][12] Clinical Development - LIXTE is currently conducting proof-of-concept trials for LB-100 in various cancer types, including Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [10] - The company has reported prolonged disease stabilization and partial response in patients during early-stage clinical trials [6][10] - The editorial supports LIXTE's research strategy, validating the unique and radical approach of LB-100 in cancer treatment [12]